Reuters Health News Summary

The fast-changing landscape, which includes the expected entry of new drugs and generic competition, has led to a recalculation of what the peak will be and when those heights may be ⁠reached, analysts and investors say. Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter Medical equipment maker Revvity handily beat fourth-quarter estimates ⁠and forecast 2026 revenue ‌and profit above Wall Street expectations on Monday, betting on continued strength in its diagnostics business even as weakness in academic research funding persists.

Following is a summary of current health news briefs.

EU advises lower toxin limit in baby formula after global recalls

The EU's food safety body said on Monday the threshold for ‌the cereulide toxin at the centre of a global infant formula recall should be cut by more than half, a move likely to prompt further product withdrawals. Cereulide, a toxin that ⁠can cause nausea and vomiting, has been detected in ingredients from a Chinese factory supplying major formula makers including Nestle, Danone and Lactalis.

US FDA declines to approve Aquestive's oral drug for allergic reactions

Aquestive Therapeutics said on Monday the U.S. Food and Drug administration has ​declined to approve its oral drug for severe allergic reactions. The company said it received a so-called complete response letter, dated ‍January 30, from the regulator that focused on how the product, Anaphylm, is packaged and used, and not on how it works or is made.

Sanofi's genetic disorder drug shows mixed results in late-stage trials

French drugmaker Sanofi said on Monday that its experimental genetic disorder treatment showed promise in a late-stage ⁠study of ‌patients with a type of ⁠Gaucher disease, but failed to meet the main goal in a separate trial. The oral drug, venglustat, was being tested in patients with Fabry disease and type ‍3 Gaucher disease. Both inherited conditions are caused by enzyme deficiencies that lead to the accumulation of toxic substances in the body.

Analysis-Obesity market ​sales potential tightens as Novo and Lilly enter new era

The long-held Wall Street expectation that the global market for ⁠obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U.S. prices falling for GLP-1 treatments from Novo Nordisk and ⁠Eli Lilly and competition heating up in the cash-pay consumer market. The fast-changing landscape, which includes the expected entry of new drugs and generic competition, has led to a recalculation of what the peak will be and when those heights may be ⁠reached, analysts and investors say.

Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

Medical equipment maker Revvity handily beat fourth-quarter estimates ⁠and forecast 2026 revenue ‌and profit above Wall Street expectations on Monday, betting on continued strength in its diagnostics business even as weakness in academic research funding persists. Life sciences firms are riding a wave of improving conditions ⁠in the pharmaceutical market and easing policy uncertainty, cushioning the impact of subdued spending ‍by universities and research institutions.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)